Anne S De Groot
Overview
Explore the profile of Anne S De Groot including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
186
Citations
3105
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Wang C, Yang J, Testa J, Gill M, Leonard M, De Groot A
Prev Chronic Dis
. 2024 Nov;
21:E92.
PMID: 39571088
Introduction: We conducted a retrospective cohort study to evaluate changes in metabolic biomarkers among participants in Bridging the [Health Equity] Gap (BTG), a free program run by Clínica Esperanza/Hope Clinic...
2.
Crippin T, Tounkara K, Munir H, Squibb E, Piotrowski C, Koita O, et al.
Vaccines (Basel)
. 2024 Sep;
12(9).
PMID: 39340049
Cervical cancer (CC) is the second most common cancer in Western Africa, accounting for 12,000 cases and 6000 deaths annually. While vaccination against human papilloma virus (HPV) and CC screenings...
3.
Roberts B, Mattei A, Howard K, Weaver J, Liu H, Lelias S, et al.
Front Pharmacol
. 2024 Aug;
15:1363139.
PMID: 39185315
Advances in synthetic peptide synthesis have enabled rapid and cost-effective peptide drug manufacturing. For this reason, peptide drugs that were first produced using recombinant DNA (rDNA) technology are now being...
4.
Sugiyama N, Terry F, Gutierrez A, Hirano T, Hoshi M, Mizuno Y, et al.
Front Immunol
. 2024 May;
15:1377911.
PMID: 38812524
Hypothesis: While conventional in silico immunogenicity risk assessments focus on measuring immunogenicity based on the potential of therapeutic proteins to be processed and presented by a global population-wide set of...
5.
Mattei A, Gutierrez A, Seshadri S, Tivin J, Ardito M, Rosenberg A, et al.
MAbs
. 2024 Mar;
16(1):2333729.
PMID: 38536724
In silico immunogenicity risk assessment has been an important step in the development path for many biologic therapeutics, including monoclonal antibodies. Even if the source of a given biologic is...
6.
Richard G, Ruggiero N, Steinberg G, Martin W, De Groot A
Expert Rev Vaccines
. 2024 Jan;
23(1):205-212.
PMID: 38189107
Introduction: Clinical trials of personalized cancer vaccines have shown that on-demand therapies that are manufactured for each patient, result in activated T cell responses against individual tumor neoantigens. However, their...
7.
Miah S, Lelias S, Gutierrez A, McAllister M, Boyle C, Moise L, et al.
Front Immunol
. 2023 Dec;
14:1290688.
PMID: 38124752
Pathogens escape host defenses by T-cell epitope mutation or deletion (immune escape) and by simulating the appearance of human T cell epitopes (immune camouflage). We identified a highly conserved, human-like...
8.
Haltaufderhyde K, Roberts B, Khan S, Terry F, Boyle C, McAllister M, et al.
AAPS J
. 2023 Dec;
26(1):6.
PMID: 38114731
No abstract available.
9.
De Groot A, Khan S, Mattei A, Lelias S, Martin W
Front Immunol
. 2023 Nov;
14:1215939.
PMID: 38022550
Biologics developers are moving beyond antibodies for delivery of a wide range of therapeutic interventions. These non-antibody modalities are often based on 'natural' protein scaffolds that are modified to deliver...
10.
Ricotti S, Garay A, Etcheverrigaray M, Amadeo G, De Groot A, Martin W, et al.
Clin Immunol
. 2023 Nov;
257:109831.
PMID: 37931868
IFNβ (recombinant interferon Beta) has been widely used for the treatment of Multiple sclerosis for the last four decades. Despite the human origin of the IFNβ sequence, IFNβ is immunogenic,...